Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00076401 · ClinicalTrials.gov registry record · Phase 2
A Study of Motexafin Gadolinium for the Treatment of Chronic Lymphocytic Leukemia (CLL)
A Phase 2 study, sponsored by Pharmacyclics.
- Terminated
- Registry status
- Phase 2
- Development phase
- 27
- Enrollment target
NCT00076401 is a Phase 2 study that was terminated before completion, run by Pharmacyclics. The registered enrollment target is 27 participants.
The verdict
NCT00076401, a Phase 2 study, was terminated before completion, sponsored by Pharmacyclics.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 27 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if the drug motexafin gadolinium will be an effective treatment for patients who have chronic lymphocytic leukemia (CLL) that has come back after treatment or that has stopped responding to treatment.
Interventions
- DRUG Motexafin gadolinium
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00076401
The ClinicalTrials.gov registry entry for NCT00076401 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pharmacyclics, which has 54 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Motexafin gadolinium is the first listed.
NCT00076401 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00076401 about?
NCT00076401 is a clinical study titled "A Study of Motexafin Gadolinium for the Treatment of Chronic Lymphocytic Leukemia (CLL)". The purpose of this study is to determine if the drug motexafin gadolinium will be an effective treatment for patients who have chronic lymphocytic leukemia (CLL) that has come back after treatment or that has stopped responding to treatment.
What is the current status of trial NCT00076401?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 27 participants.
What interventions are being tested in trial NCT00076401?
The interventions under investigation include: Motexafin gadolinium (DRUG).
Who is sponsoring clinical trial NCT00076401?
This trial is sponsored by Pharmacyclics, which has 54 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.